MYGN Message Board - Msg: 3985335

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MYGN

MYGN 6.360

-2.0%

1:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lee Allgood who wrote (13)	4/7/1998 11:39:00 AM
From: Roger Steiner	Read Replies (1) of 29

from Briefing.com: Myriad Genetics Inc. (MYGN) 20 1/2 +3/8: Lehman Brothers thinks that developer and operator of genetic predisposition testing lab could be a winner in Zeneca Tamoxifen breast cancer drug breakthrough; MYGN well positioned to benefit from Tamoxifen data because it offers genetic test for predisposition to breast cancer that should demonstrate whether women will benefit from Tamoxifen treatment; rates issue a "buy" and increases its 12-month price target from $41 to $46 on improved outlook for market penetration..... Anybody still in this stock? Roger

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next